Monday, March 27 at 1:30 PM EST

Please join Parent Project Muscular Dystrophy and Akashi Therapeutics as we host a webinar Monday, March 27 at 1:30 PM ET to discuss HT-100 and next steps for the clinical program.

Akashi CEO Marc Blaustein will present data from the previous clinical program of HT-100 and discuss FDA’s recent decision to allow the clinical development of HT-100 to resume, and leave time for discussion and fielding of questions.

Speakers:

• Pat Furlong
  Founding President & CEO, Parent Project Muscular Dystrophy
• Annie Kennedy
  Senior Vice President of Legislation and Public Policy, Parent Project Muscular Dystrophy
• Marc Blaustein
  CEO, Akashi Therapeutics

To Participate:

1. Visit ReadyTalk.com and use access code 9449985. (Be sure to test your computer beforehand)
2. Audio Dial-In Information:
   • U.S. & Canada: Dial 1.866.740.1260 and use the Access Code 9449985
   • Outside the U.S. and Canada: Lookup your number

Submit Questions:

Please submit questions in advance to ryan@parentprojectmd.org, with “Akashi Webinar” in the subject line by Friday, March 24th at 5pm eastern.